Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and
RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive
disease.